> top > docs > PubMed:32401405 > annotations

PubMed:32401405 JSONTXT

Annnotations TAB JSON ListView MergeView

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-130 Sentence denotes Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: risks and benefits at the time of COVID-19 pandemic.
T2 131-300 Sentence denotes The antimalarial drug hydroxychloroquine (HCQ) has long been used as a disease-modifying antirheumatic drug for the treatment of several inflammatory rheumatic diseases.
T3 301-425 Sentence denotes Over the last three decades, various studies have shown that HCQ plays also a role in the regulation of glucose homeostasis.
T4 426-782 Sentence denotes Although the mechanisms of action underlying the glucose-lowering properties of HCQ are still not entirely clear, evidence suggests that this drug may exert multifaceted effects on glucose regulation, including improvement of insulin sensitivity, increase of insulin secretion, reduction of hepatic insulin clearance and reduction of systemic inflammation.
T5 783-946 Sentence denotes Preliminary studies have shown the safety and efficacy of HCQ (at a dose ranging from 400 to 600 mg/day) in patients with type 2 diabetes over a short-term period.
T6 947-1066 Sentence denotes In 2014, HCQ has been approved in India as an add-on hypoglycemic agent for patients with uncontrolled type 2 diabetes.
T7 1067-1231 Sentence denotes However, large randomized controlled trials are needed to establish the safety and efficacy profile of HCQ in patients with type 2 diabetes over a long-term period.
T8 1232-1386 Sentence denotes With regard to the COVID-19 pandemic, several medications (including HCQ) have been used as off-label drugs due to the lack of proven effective therapies.
T9 1387-1472 Sentence denotes However, emerging evidence shows limited benefit from HCQ use in COVID-19 in general.
T10 1473-1750 Sentence denotes The aim of this manuscript is to comprehensively summarize the current knowledge on the antihyperglycemic properties of HCQ and to critically evaluate the potential risks and benefits related to HCQ use in patients with diabetes, even in light of the current pandemic scenario.
T11 1751-1790 Sentence denotes This article is protected by copyright.
T12 1791-1811 Sentence denotes All rights reserved.
T1 0-130 Sentence denotes Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: risks and benefits at the time of COVID-19 pandemic.
T2 131-300 Sentence denotes The antimalarial drug hydroxychloroquine (HCQ) has long been used as a disease-modifying antirheumatic drug for the treatment of several inflammatory rheumatic diseases.
T3 301-425 Sentence denotes Over the last three decades, various studies have shown that HCQ plays also a role in the regulation of glucose homeostasis.
T4 426-782 Sentence denotes Although the mechanisms of action underlying the glucose-lowering properties of HCQ are still not entirely clear, evidence suggests that this drug may exert multifaceted effects on glucose regulation, including improvement of insulin sensitivity, increase of insulin secretion, reduction of hepatic insulin clearance and reduction of systemic inflammation.
T5 783-946 Sentence denotes Preliminary studies have shown the safety and efficacy of HCQ (at a dose ranging from 400 to 600 mg/day) in patients with type 2 diabetes over a short-term period.
T6 947-1066 Sentence denotes In 2014, HCQ has been approved in India as an add-on hypoglycemic agent for patients with uncontrolled type 2 diabetes.
T7 1067-1231 Sentence denotes However, large randomized controlled trials are needed to establish the safety and efficacy profile of HCQ in patients with type 2 diabetes over a long-term period.
T8 1232-1386 Sentence denotes With regard to the COVID-19 pandemic, several medications (including HCQ) have been used as off-label drugs due to the lack of proven effective therapies.
T9 1387-1472 Sentence denotes However, emerging evidence shows limited benefit from HCQ use in COVID-19 in general.
T10 1473-1750 Sentence denotes The aim of this manuscript is to comprehensively summarize the current knowledge on the antihyperglycemic properties of HCQ and to critically evaluate the potential risks and benefits related to HCQ use in patients with diabetes, even in light of the current pandemic scenario.
T11 1751-1790 Sentence denotes This article is protected by copyright.
T12 1791-1811 Sentence denotes All rights reserved.

PubMed_ArguminSci

Id Subject Object Predicate Lexical cue
T1 131-201 DRI_Background denotes The antimalarial drug hydroxychloroquine (HCQ) has long been used as a
T2 234-300 DRI_Background denotes drug for the treatment of several inflammatory rheumatic diseases.
T3 301-425 DRI_Background denotes Over the last three decades, various studies have shown that HCQ plays also a role in the regulation of glucose homeostasis.
T4 426-782 DRI_Challenge denotes Although the mechanisms of action underlying the glucose-lowering properties of HCQ are still not entirely clear, evidence suggests that this drug may exert multifaceted effects on glucose regulation, including improvement of insulin sensitivity, increase of insulin secretion, reduction of hepatic insulin clearance and reduction of systemic inflammation.
T5 783-946 DRI_Background denotes Preliminary studies have shown the safety and efficacy of HCQ (at a dose ranging from 400 to 600 mg/day) in patients with type 2 diabetes over a short-term period.
T6 947-1066 DRI_Background denotes In 2014, HCQ has been approved in India as an add-on hypoglycemic agent for patients with uncontrolled type 2 diabetes.
T7 1067-1231 DRI_Background denotes However, large randomized controlled trials are needed to establish the safety and efficacy profile of HCQ in patients with type 2 diabetes over a long-term period.
T8 1232-1386 DRI_Background denotes With regard to the COVID-19 pandemic, several medications (including HCQ) have been used as off-label drugs due to the lack of proven effective therapies.
T9 1387-1472 DRI_Approach denotes However, emerging evidence shows limited benefit from HCQ use in COVID-19 in general.
T10 1473-1750 DRI_FutureWork denotes The aim of this manuscript is to comprehensively summarize the current knowledge on the antihyperglycemic properties of HCQ and to critically evaluate the potential risks and benefits related to HCQ use in patients with diabetes, even in light of the current pandemic scenario.

LitCovid-OGER-BB

Id Subject Object Predicate Lexical cue
T1 32-50 CHEBI:5801;DG_20;CHEBI:5801 denotes hydroxychloroquine
T2 112-120 SP_7 denotes COVID-19
T3 135-147 CHEBI:35718;CHEBI:35718 denotes antimalarial
T4 148-152 CHEBI:23888;CHEBI:23888 denotes drug
T5 153-171 CHEBI:5801;CHEBI:5801;DG_20 denotes hydroxychloroquine
T6 220-233 CHEBI:67079;CHEBI:67079 denotes antirheumatic
T7 234-238 CHEBI:35842;CHEBI:35842 denotes drug
T8 391-404 GO:0042593 denotes regulation of
T9 405-412 CHEBI:17234;CHEBI:17234;GO:0042593 denotes glucose
T10 413-424 GO:0042593 denotes homeostasis
T11 475-482 CHEBI:17234;CHEBI:17234 denotes glucose
T12 568-572 CHEBI:23888;CHEBI:23888 denotes drug
T13 607-614 CHEBI:17234;CHEBI:17234 denotes glucose
T14 615-625 GO:0065007 denotes regulation
T15 652-659 PR:000009054 denotes insulin
T16 685-692 PR:000009054 denotes insulin
T17 717-724 UBERON:0002107 denotes hepatic
T18 725-732 PR:000009054 denotes insulin
T19 1000-1018 CHEBI:35526;CHEBI:35526 denotes hypoglycemic agent
T20 1251-1259 SP_7 denotes COVID-19
T21 1278-1289 CHEBI:23888;CHEBI:23888 denotes medications
T22 1334-1339 CHEBI:23888;CHEBI:23888 denotes drugs
T23 1452-1460 SP_7 denotes COVID-19

hydroxychloroquine

Id Subject Object Predicate Lexical cue hp_id
T1 905-920 Phenotype denotes type 2 diabetes http://purl.obolibrary.org/obo/HP_0005978
T2 1050-1065 Phenotype denotes type 2 diabetes http://purl.obolibrary.org/obo/HP_0005978
T3 1191-1206 Phenotype denotes type 2 diabetes http://purl.obolibrary.org/obo/HP_0005978